Lingering difficulties in making all Kymriah product to FDA specifications has meant Novartis can't always charge for the cell therapy. New data at ASH could help the pharma's case.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,